Tranexamic acid for acute intracerebral haemorrhage growth based on imaging assessment (TRAIGE): a multicentre, randomised, placebo-controlled trial.
Jingyi LiuXiming NieHong-Qiu GuQi ZhouHaixin SunYing TanDacheng LiuLina ZhengJiahui ZhaoYan WangYibin CaoHaomeng ZhuYunpeng ZhangLijin YiYuehua PuMiao WenZhonghua YangShengjun SunWenzhi WangXingquan ZhaoLi-Ping LiuYong-Jun WangPublished in: Stroke and vascular neurology (2021)
Among patients susceptible to haemorrhage expansion treated within 8 hours of stroke onset, tranexamic acid did not significantly prevent intracerebral haemorrhage growth. Larger studies are needed to assess safety and efficacy of tranexamic acid in intracerebral haemorrhage patients.
Keyphrases
- double blind
- end stage renal disease
- clinical trial
- study protocol
- newly diagnosed
- ejection fraction
- chronic kidney disease
- high resolution
- liver failure
- peritoneal dialysis
- open label
- randomized controlled trial
- prognostic factors
- cross sectional
- placebo controlled
- drug induced
- hepatitis b virus
- aortic dissection
- blood brain barrier
- subarachnoid hemorrhage